Autolus Therapeutics plc announced the presentation of preliminary data from the Phase 1 CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), as well as additional analyses from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology $(ASH)$ Annual Meeting. The CATULUS trial data showed a 95.5% overall response rate in pediatric patients, including those with high-risk relapse and primary CNS relapse, with low rates of high-grade cytokine release syndrome $(CRS)$ and immune effector cell-associated neurotoxicity syndrome (ICANS). The FELIX study highlighted product cell phenotype and CAR T-cell persistence at three months as potential predictors of long-term remission. Real-world data from the US commercial launch of obe-cel, collected by the ROCCA consortium, demonstrated high response rates and low levels of high-grade CRS and ICANS, consistent with clinical trial findings.